Table 1 Demographic, clinical, and serological characteristics of the study population
IIM baseline; n=28 | IIM 2 years; n=28 | Control; n=26 | |
|---|---|---|---|
Demography, organ involvements | |||
Mean age at onset, years, Mean ± SEM | 41.9 ± 1.6 | NA | 43.7 ± 0.7 |
Sex (female/male) n | 25/3 (89/11%) | 25/3 (89/11%) | 23/3 (88/12%) |
Diagnosis (PM/DM) | 21/7 (77%/23%) | 21/7 (77%/23%) | NA |
Interstitial lung disease | 35.7% | 35.7% | NA |
Raynaud sign | 32.1% | 32.1% | NA |
Dysphagia | 14.2% | 14.2% | NA |
Arthritis | 71.4% | 71.4% | NA |
SBP, mmHg | 120 ± 2 | 130 ±1 | 122 ±2 |
DBP, mmHg | 76 ± 1 | 78±1 | 73±1 |
HR, beat/min | 85 ± 1 | 79±2 | 76±3 |
Antibodies | Myositis profile 3 Blot Strip | Euroline Myositis Antigen Profile4 | NA |
Anti-Jo1 | 6 | 6 | NA |
Anti-PL7 | 0 | 0 | NA |
Anti-PL12 | 0 | 0 | NA |
Anti-EJ | 0 | 0 | NA |
Anti-OJ | 0 | 0 | NA |
Anti-SRP | 0 | 0 | NA |
Anti-Mi2 | 0 | 1 | NA |
Anti-NXP2 | 0 | 2 | NA |
Anti-MDA5 | 0 | 0 | NA |
Anti-TIF1gamma | 0 | 1 | NA |
Anti-Pm/scl-100 | 1 | 1 | NA |
Anti-Pm/scl-75 | 3 | 3 | NA |
Anti-Ku | 0 | 0 | NA |
Anti-Ro52 | 6 | 6 | NA |
Anti-DNS | 0 | 0 | NA |
Immunsupressive therapy | |||
Corticosteroid | 28 | 28 | 0 |
Cyclosporin-A | 4 | 4 | 0 |
Methotrexate | 0 | 5 | 0 |
Cyclophosphamid | 0 | 2 | 0 |
Rituximab | 0 | 2 | 0 |
Disease course | |||
Monophasic (without relapse) n | NA | 16 | NA |
Polyphasic (with relapse) n | NA | 12 | NA |